Hemantane

Last updated

Hemantane
Hemantane.svg
Clinical data
Other namesHymantane; Gimantan; N-Adamant-2-ylhexamethyleneimine; N-(2-Adamantyl)hexamethyleneimine
Identifiers
  • 1-(2-adamantyl)azepane
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C16H27N
Molar mass 233.399 g·mol−1
3D model (JSmol)
  • C1CCCN(CC1)C2C3CC4CC(C3)CC2C4
  • InChI=1S/C16H27N/c1-2-4-6-17(5-3-1)16-14-8-12-7-13(10-14)11-15(16)9-12/h12-16H,1-11H2
  • Key:JAROVUWOMYMQCW-UHFFFAOYSA-N

Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed. [1] It was developed and studied in Russia. [1]

Contents

It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, as a selective MAO-B inhibitor, and as showing various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum. [1] [2] The drug has also been theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects. [1] Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation. [1]

The drug was first described by 2000. [3] [4]

The dosage of gimantan is standardized to 50mg tablet strength. [5]

Chemistry

Gimantan is synthesized, according to the Leuckart reaction, by heating adamantanone and azepane in the presence of formic acid. [6] [7] [8]


See also

References

  1. 1 2 3 4 5 Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2): 83–91. doi:10.1134/S1819712411010028. ISSN   1819-7124.
  2. ↑ Fischler PV, Soyka M, Seifritz E, Mutschler J (2022). "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Frontiers in Pharmacology. 13: 927703. doi: 10.3389/fphar.2022.927703 . PMC   9574013 . PMID   36263121.
  3. ↑ Val'dman EA (2000). "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (5): 3–6. PMID   11109514.
  4. ↑ Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA (2001). "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 64 (6): 13–16. PMID   11871228.
  5. ↑ Tsvetkova EA, Volkova MY, Stepanenko OB, Kislyak NA, Shcherbakova OV, Avdyunina NI, et al. (January 2002). "Gimantan Tablets: Analysis and Standardization". Pharmaceutical Chemistry Journal. 36 (1): 48–50. doi:10.1023/A:1015761110991.
  6. ↑ Sergeeva MS, Grushevskaya LN, Pyatin BM, Avdyunina NI, Gaevaya LM, Klumova VS, et al. (November 2011). "Pharmaceutical analysis and standardization of gimantan parenteral dosage form". Pharmaceutical Chemistry Journal. 45 (8): 499–502. doi:10.1007/s11094-011-0664-1.
  7. ↑ Seredenin SB, Voronina TA, Avdyunina NI, Pyatin BM, Morozov IS, Bykov NP, et al. (2010). "SU1825499 "N-(2-adamantyl)hexamethyleneimine hydrochloride with anticataleptic activity". Byull. Izobret. (in Russian). 4.
  8. ↑ Tsvetkova EA, Volkova MY, Stepanenko OB, Avdyunina NI, Bol'shakova RF, Pyatin BM (November 2001). "Analysis and Standardization of the New Domestic Antiparkinsonian Drug Gimantan". Pharmaceutical Chemistry Journal. 35 (11): 635–638. doi:10.1023/A:1015158213734.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.